Media headlines about Atrion Corporation (NASDAQ:ATRI) have trended somewhat positive on Sunday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atrion Corporation earned a news impact score of 0.04 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 45.8114974219335 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Separately, BidaskClub raised Atrion Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 29th.

Shares of Atrion Corporation (NASDAQ ATRI) opened at 622.95 on Friday. Atrion Corporation has a 52-week low of $393.96 and a 52-week high of $691.95. The company has a market capitalization of $1.15 billion, a PE ratio of 34.90 and a beta of 0.91. The stock has a 50 day moving average price of $638.50 and a 200 day moving average price of $538.15.

Atrion Corporation (NASDAQ:ATRI) last posted its earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share for the quarter. The business had revenue of $36.16 million for the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. On average, analysts predict that Atrion Corporation will post $9.90 earnings per share for the current fiscal year.

In related news, Chairman Emile A. Battat sold 1,217 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $564.04, for a total transaction of $686,436.68. Following the transaction, the chairman now directly owns 150,797 shares of the company’s stock, valued at approximately $85,055,539.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Emile A. Battat sold 100 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $585.50, for a total value of $58,550.00. Following the transaction, the chairman now directly owns 149,081 shares in the company, valued at $87,286,925.50. The disclosure for this sale can be found here. Insiders have sold a total of 3,392 shares of company stock worth $1,900,070 over the last three months. 24.23% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Atrion Corporation (ATRI) Receiving Somewhat Favorable Press Coverage, Report Shows” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/atrion-corporation-atri-receiving-somewhat-favorable-press-coverage-report-shows.html.

About Atrion Corporation

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Insider Buying and Selling by Quarter for Atrion Corporation (NASDAQ:ATRI)

Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.